BOTHELL, Wash., June 16 /PRNewswire-FirstCall/ -- Cardiac Science today announced the launch of Pyramis(R) 6.2, the flagship HeartCentrix(R) data management product for the hospital market. Pyramis 6.2 centralizes diagnostic cardiology data for rapid access across all facilities within a hospital network. Cardiac Science is a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)
"Hospitals love the remote access features," said Rene Mitchell, director of diagnostic marketing for Cardiac Science. "And they don't have to invest in custom connectivity software or hardware, since Pyramis 6.2 communicates with all Health Level 7 (HL7) interfaces on an open architecture, thus reducing hospital expenditures."
Pyramis is multi-modal. It supports hospitals' preferred electrocardiogram devices (ECGs), stress testing equipment, Holter monitors, and other devices on a single platform -- and provides bi-directional communication when paired with most Quinton(R) and Burdick(R) devices. Pyramis 6.2:
Among ECG management systems, Pyramis provides a unique-to-the-industry feature: Digital Imaging and Communications in Medicine (DICOM) images can be sent to Picture Archiving and Communication Systems (PACS) and Hospital Information Systems (HIS) so end users can review not just single but multi- modality recordings (ECG, stress, and Holter) in one application.
Stephen French, program manager-PACS for WellSpan Health of Pennsylvania, switched from GE MUSE to Pyramis. He explained, "We needed a stable system for new and current hardware. Pyramis is better for ECG and stress tests on a single system, and waveforms and stress tests are "waveform enabled" and viewable via Millennium (Cerner's HIS system). With Pyramis, we have remote access via any Wellspan access device -- and remote access at home for all clinicians."
"Along with the rest of the HeartCentrix connectivity products, Pyramis reinforces our commitment to the markets we serve: Everything Cardiac Science makes needs to connect to your systems to save you money, eliminate implementation headaches, and help you provide better patient care," added Tony Titus, vice president of marketing for Cardiac Science.
Pyramis can be purchased as a software-only option, and provides important clinical workflow tools including electronic signature, calipers, serial comparison, prior tests accessibility, order attachment, multi-faceted patient and test queries, tests status, overdue indicators, and data mining tools, among others.
About Cardiac Science
Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, those that infer that Cardiac Science Corporation's future revenue and profits may grow as a result of sales of Pyramis and the HeartCentrix suite of connectivity products. These statements and their underlying assumptions involve a number of risks and uncertainties and are not guarantees of future performance. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward looking. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks that are more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2007. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
CSCX-G
CONTACT: Mike Matysik, Sr. Vice President and CFO of Cardiac Science
Corporation, +1-425-402-2009; or investors, Jenifer Kirtland Inc.,
+1-415-896-6820, or media, Christopher Gale, +1-201-646-5431, or
+1-203-570-4681, cgale@evcgroup.com, both of EVC Group, for Cardiac Science
Corporation
Web site: http://www.cardiacscience.com/
